Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786416 | 0.93 | SLC6A4 (0.41) | STIM1ORAI1SLC6A4NPSR1PTPN1 | |
| SCHEMBL21786530 | 0.92 | MAPT (0.40) | STIM1ORAI1SLC6A4NPSR1MEN1 | |
| SCHEMBL21786534 | 0.92 | PTGER1 (0.38) | STIM1ORAI1KMT2APTPN1PTPN2 | |
| SCHEMBL21786497 | 0.91 | PTGER1 (0.39) | STIM1ORAI1SLC6A4NPSR1MEN1 | |
| SCHEMBL21786479 | 0.91 | STIM1 (0.36) | STIM1ORAI1SLC6A4NPSR1KMT2A | |
| SCHEMBL21786614 | 0.90 | PTGS2 (0.39) | NPSR1PTPN1PTPN2PTPN6PTGS1 | |
| SCHEMBL21786593 | 0.88 | MRGPRX4 (0.40) | STIM1ORAI1SLC6A4NPSR1MEN1 | |
| SCHEMBL22791183 | 0.88 | MAPT (0.38) | NPSR1MEN1KMT2APTPN1PTPN2 | |
| SCHEMBL21786611 | 0.87 | SLC6A4 (0.39) | STIM1ORAI1SLC6A4NPSR1PTGS1 | |
| SCHEMBL21786465 | 0.87 | SLC6A4 (0.39) | STIM1ORAI1SLC6A4NPSR1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115120-A1 | COMPOSITIONS, METHODS AND USES OF COMBINATION TREATMENTS FOR BLOOD CANCERS | UNIVERSITY OF NEW BRUNSWICK (CA) | 2023-04-13 | — | — | US | claimed |
| EP-4117653-A1 | COMPOSITION AND USE OF A CAFFEIC ACID PHENETHYL ESTER (CAPE) COMPOUND TO TREAT CANCER | University of New Brunswick (CA) | 2023-01-18 | — | — | EP | claimed |
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | FOUNDATION MEDICINE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4740951-A2 | IGH REARRANGEMENTS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4267767-B1 | IGH REARRANGEMENTS AND USES THEREOF | FOUND MEDICINE INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4658641-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | Xeniom GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025137355-A1 | PROXY BINDING FOR SCREENING THERAPEUTIC COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025128887-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE ENRICHMENT OF METHYLATION SIGNAL | FOUNDATION MEDICINE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250201339-A1 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025122504-A1 | ESR1 MUTATIONS, ESR1 CO-OCCURRING MUTATIONS, AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20220280590-A1 | USE OF INHIBITORS OF YAP AND SOX2 FOR THE TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022147163-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022140420-A1 | IGH REARRANGEMENTS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020046382-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115120-A1 | COMPOSITIONS, METHODS AND USES OF COMBINATION TREATMENTS FOR BLOOD CANCERS | MYC, SP1, MYCBP | STIM1 3752/4885ORAI1 4666/4885SLC6A4 4764/4885 |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | STIM1 3524/4885ORAI1 4867/4885SLC6A4 4129/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | STIM1 3524/4885ORAI1 4867/4885SLC6A4 4129/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | STIM1 3524/4885ORAI1 4867/4885SLC6A4 4129/4885 |
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | PLK1, MYC, PLK4 | STIM1 3076/4885ORAI1 3707/4885SLC6A4 1594/4885 |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | MSH2, MSH6, PMS2 | STIM1 2246/4885ORAI1 4517/4885SLC6A4 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.